![γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment - ScienceDirect γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0024320520317677-gr1.jpg)
γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment - ScienceDirect
Recent developments of small molecule γ-secretase modulators for Alzheimer's disease - RSC Medicinal Chemistry (RSC Publishing)
![Gamma-Secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planarian regeneration by inhibiting Notch signaling pathway - ScienceDirect Gamma-Secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planarian regeneration by inhibiting Notch signaling pathway - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0048969721018039-ga1.jpg)
Gamma-Secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planarian regeneration by inhibiting Notch signaling pathway - ScienceDirect
![Clinical trials employing γ-secretase inhibitors in the treatment of... | Download Scientific Diagram Clinical trials employing γ-secretase inhibitors in the treatment of... | Download Scientific Diagram](https://www.researchgate.net/profile/Raghu-Nataraj-2/publication/323774729/figure/tbl1/AS:745818663436294@1554828434386/Clinical-trials-employing-g-secretase-inhibitors-in-the-treatment-of-breast-cancer-2013.png)
Clinical trials employing γ-secretase inhibitors in the treatment of... | Download Scientific Diagram
![Frontiers | Targeting Amyloidogenic Processing of APP in Alzheimer's Disease | Molecular Neuroscience Frontiers | Targeting Amyloidogenic Processing of APP in Alzheimer's Disease | Molecular Neuroscience](https://www.frontiersin.org/files/Articles/558862/fnmol-13-00137-HTML-r1/image_m/fnmol-13-00137-g001.jpg)
Frontiers | Targeting Amyloidogenic Processing of APP in Alzheimer's Disease | Molecular Neuroscience
![Pharmaceuticals | Free Full-Text | BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer's Disease | HTML Pharmaceuticals | Free Full-Text | BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer's Disease | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-12-00041/article_deploy/html/images/pharmaceuticals-12-00041-g006.png)
Pharmaceuticals | Free Full-Text | BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer's Disease | HTML
![γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment - ScienceDirect γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0024320520317677-gr2.jpg)
γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment - ScienceDirect
![g-Secretase inhibitors recently or currently in clinical trials for the... | Download Scientific Diagram g-Secretase inhibitors recently or currently in clinical trials for the... | Download Scientific Diagram](https://www.researchgate.net/profile/Bart-Strooper/publication/221815851/figure/fig4/AS:601671554048008@1520461085119/g-Secretase-inhibitors-recently-or-currently-in-clinical-trials-for-the-treatment-of.png)
g-Secretase inhibitors recently or currently in clinical trials for the... | Download Scientific Diagram
![Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio | Cell Discovery Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio | Cell Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fcelldisc.2016.26/MediaObjects/41421_2016_Article_BFcelldisc201626_Fig1_HTML.jpg)
Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio | Cell Discovery
![γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/1868f81f-f9d8-44b2-8388-9a11ea18ebec/emmm201607265-abs-0001-m.jpg)
γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine
![γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/6085c13c-a424-4c4a-bd51-9074c1953510/emmm201607265-fig-0003-m.jpg)
γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine
![PDF) Three cases of apparent Vasogenic Edema (VE) from a phase 2 clinical trial of the gamma secretase Inhibitor BMS-708163 in patients with mild-to-moderate AD | Mark Meadowcroft and charles e albright - PDF) Three cases of apparent Vasogenic Edema (VE) from a phase 2 clinical trial of the gamma secretase Inhibitor BMS-708163 in patients with mild-to-moderate AD | Mark Meadowcroft and charles e albright -](https://0.academia-photos.com/attachment_thumbnails/42245696/mini_magick20190217-11029-n5b0pz.png?1550474696)